China Resources Pharmaceutical Group Limited (stock code: 3320) announced that its subsidiary, China Resources Double-Crane Pharmaceutical Co., Ltd. (“CR Double-Crane”), released unaudited financial results for the nine months ended 30 September 2025. According to the published data on the Shanghai Stock Exchange, CR Double-Crane recorded revenue of RMB 8,283,222,411.30 and net profit of RMB 1,388,212,831.84. The net decrease in cash and cash equivalents was RMB 630,388,437.05, with cash and cash equivalents amounting to RMB 2,207,726,715.86 at the end of the reporting period.

The report indicated that total assets stood at RMB 17,013,714,914.48 as of 30 September 2025, while total liabilities were RMB 4,852,945,043.03 and owner’s equity reached RMB 12,160,769,871.45. The figures were prepared in accordance with the PRC Generally Accepted Accounting Principles and have not been reviewed or audited by China Resources Pharmaceutical Group Limited’s auditors. Potential adjustments may arise from the auditing process. The financial information covers only CR Double-Crane and does not represent the overall financial status of the group.